ANRO
Alto Neuroscience, Inc. Health Care Pharmaceutical Preparations Russell 3000
$22.60Close
$721.5MMarket cap
$11.13 – $36.6452-week range
Nov 11, 2026Next report
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 38% below its 52-week high
- Distribution down-day volume 1.8× up-day volume over 50 sessions
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
38%
1wk
up 2.9%
price change
1mo
down 11.5%
price change
12-month return
up 58%
market up 11% ·
its own up 50%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.8×
price / book
Earnings yield
down 11.8%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 42%
return on equity
Free cash margin
—
-$51.8M FCF
D/E
0.11
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
6.7%
$1.51 a day · 2×ATR $19.58
RS
67 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.57
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 18.3% over the year, from 27m to 32m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026+11% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|
| Operating income | -$37.8M | -$68.6M | -$66.4M |
| Net income | -$36.3M | -$61.4M | -$63.2M |
| Earnings per share | -$9.73 | -$2.50 | -$2.19 |
| Free cash flow | -$33.9M | -$49.5M | -$51.8M |
| Cash | $82.5M | $168.2M | $176.5M |
| Long-term debt | $9.9M | $10.3M | $16.2M |
| Shareholders' equity | -$71.7M | $151.5M | $151.1M |
| Shares outstanding | 3.83m | 26.99m | 31.92m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 16, 2026 | Annual ↗ | Dec 31, 2025 | 75d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 20, 2025 | Annual ↗ | Dec 31, 2024 | 79d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 27, 2026 | Director or officer change ↗ |
| Aug 12, 2026 | Results ↗ |
| Jul 14, 2026 | Material agreement ↗ |
| Jul 13, 2026 | Results · Other events ↗ |
| May 28, 2026 | Director or officer change ↗ |
| May 13, 2026 | Director or officer change · Shareholder vote ↗ |
| May 13, 2026 | Results ↗ |
| Apr 1, 2026 | Other events ↗ |
| Mar 16, 2026 | Results ↗ |
| Mar 16, 2026 | Material agreement · Unregistered share sale · Other events ↗ |
| Nov 12, 2025 | Results ↗ |
| Oct 20, 2025 | Material agreement · Agreement ended · Unregistered share sale · Other events ↗ |